Market Cap (In USD)
85.43 Thousand
Revenue (In USD)
3.76 Million
Net Income (In USD)
-10.62 Million
Avg. Volume
958.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.02-0.55
- PE
- -
- EPS
- -
- Beta Value
- 1.118
- ISIN
- US43358Y2028
- CUSIP
- 43358Y103
- CIK
- 1383701
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Susan A. Knudson
- Employee Count
- -
- Website
- https://www.histogen.com
- Ipo Date
- 2013-07-25
- Details
- Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
More Stocks
-
7282
-
VIBE
-
0R1D
-
ZLABZai Lab Limited
ZLAB
-
3153
-
ESP
-
SZGSalzgitter AG
SZG
-
DMGI